Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
InterAACT 2 trial: what clinicians have said so far
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
- NCT04472429 ↗
- Completed
- Incyte Corporation
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on InterAACT 2 (retifanlimab in locally recurrent or metastatic squamous cell anal carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on InterAACT 2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 21 posts on X | |
| 5 YouTube videos | |
| 5 podcast episodes | |
| 1 video on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Squamous Cell Carcinoma of the Anal Canal
- Interventions
- carboplatin; paclitaxel; retifanlimab
- Arms
- Group A : carboplatin+paclitaxel+placebo · Placebo comparator
- Group B : carboplatin+paclitaxel+retifanlimab · Experimental
- Enrollment
- 308
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- Incyte Corporation
- Start
- Nov 9, 2020
- Primary completion
- Apr 15, 2024
- Results posted
- Yes
- Registry record
- NCT04472429 · updated Sep 25, 2026
Publications
linked from the registry- Rao S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, Morano F, Roy A, Dahan L, Tamberi S, Dhadda AS, Saunders MP, Casanova N, Guimbaud R, Lievre A, Maurel J, Fakih M, Tian C, Harrison J, Jones MM, Cornfeld M, Spano JP, Rochefort P; POD1UM-303/InterAACT-2 study investigators. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial. Lancet. 2025 Jun 14;405(10495):2144-2152. doi: 10.1016/S0140-6736(25)00631-2. PubMed 40517007
- Rao S, Jones M, Bowman J, Tian C, Spano JP. POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Front Oncol. 2022 Aug 24;12:935383. doi: 10.3389/fonc.2022.935383. eCollection 2022. PubMed 36091159